New antipsychotics in long-term treatment of schizophrenia;Der einsatz neuer antipsychotika in der langzeittherapie schizophrener patienten

Psychopharmakotherapie

Volumn 11, Issue 1, 2004, Pages 2-10

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Depot neuroleptics; Long term treatment; Oral long term treatment; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SERTINDOLE; ZOTEPINE;

CLINICAL FEATURE; CLINICAL TRIAL; DRUG FORMULATION; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; PROGNOSIS; PSYCHOPHARMACOTHERAPY; RELAPSE; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 1242330420     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Arato M, O'Connor R, Meltzer HY, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17: 207-15.
2. Bäuml J, Kissling W, Meurer C, Wais A, et al. Informationszentrierte Angehörigengruppe zur Complianceverbesserung bei schizophrenen Patienten. Psychiatr Prax 1991;18:48-54.
3. Beasley C, Hamilton S, Dossenbach M. Relapse prevention with olanzapine. Eur Neuropsychopharmacol 2000;10(Suppl 3):S304.
4. Buchkremer G, Schulze-Mönking H, Holle R, Hornung WP. The impact of therapeutic relatives' groups on the course of illness of schizophrenic patients. Eur Psychiat 1995;10: 17-27.
5. Cheung HK. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs. Br J Psychiat 1981;138:490-4.
6. Chue P, Eerdekens M, Augustyns I, Lachaux B, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr Bull 2002;53:174-5.
7. Cooper SJ, Butler A, Tweed J, Welch C, et al. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacology (Berl) 2000;150:237-43.
8. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
9. Crawford R, Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry. 1974;124:385-91.
10. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346: 16-22.
11. Daniel DG, Wozniak P, Mack RJ, McCarthy BG. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9.
12. Davis JM, Matalon L, Watanabe MD, Blake L, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73.
13. Dellva MA, Tran P, Tollefson GD, Wentley AL, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-7.
14. Eerdekens M, Fleischhacker WW, Xie Y, Gefvert O. Long-term safety of long-acting risperidone microspheres. Schizophr Bull 2002;53:174
15. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32: 683-97.
16. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978;8:59-70.
17. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-51.
18. Gaebel W. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment? Int Clin Psychopharmacol 1995;9(Suppl 5):11-6.
19. Hirsch SR, Gaind R, Rohde P, Stevens B, et al. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Br Med J 1973;1: 633-7.
20. Hogarty GE, Goldberg SC. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry 1973;28:54-64.
21. Hogarty GE, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-years relapse rates. Arch Gen Psychiatry 1974;31:603-8.
22. Hogarty GE, Schooler NR, Ulrich R, Mussare F, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36: 1283-94.
23. Jolley AG, Hirsch SR, Morrison E, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301:837-42.
24. Kane JM, Aguglia E, Altamura AC, Ayuso-Gutierrez JL, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55-66.
25. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
26. Leff J, Wing JK. Trials of maintenance therapy in schizophrenia. Br Med J 1971;3:599-604.
27. Leucht S, Barnes T, Kissling W, Engel R, Kane JM. Relapse prevention in schizophrenia with new antipsychotics: a meta-analysis of randomized controlled trials. Am J Psychiatry 2003;160:1209-22.
28. Lieberman JA, Koreen AR, Chakos M, Sheitman B, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(Suppl 9):5-9.
29. Loo H, Poirier-Litter MF, Theron M, Rein W, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170: 18-22.
30. Marder SR, Van Putten T, Mintz J, Lebell M, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. Arch Gen Psychiatry 1987;44:518-21.
31. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003;160: 1405-12.
32. Meltzer HY, Alphs L, Green A, Altamura AC, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
33. Möller HJ. Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K (Hrsg). Leitlinien neuroleptischer Therapie. Berlin, Heidelberg, New York: Springer, 1990: 97-115.
34. Möller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000;1:75-91.
35. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000;1:204-14.
36. Möller HJ. Antipsychotic agents - gradually improving treatment. Br J Psychiat. Im Druck.
37. Möller HJ. Depressive Comorbidität/Co-syndromalität im Rahmen schizophrener Psychosen und ihre Therapie. In: Fleischhacker WW, Hummer M (Hrsg). Schizophrene Störungen - State of the art. Innsbruck: VIP-Verlag. Im Druck.
38. Möller HJ, Deister A. Schizophrenie. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg). Psychiatrie und Psychotherapie, 2. Aufl. Berlin, Heidelberg, New York: Springer, 2002: 1051-122.
39. Möller HJ, Gagiano CA, Addington DE, Von Knorring L, et al. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. Int Clin Psychopharmacol 1998;13:99-106.
40. Möller HJ, Kissling W, Stoll KD, Wendt G. Psychopharmakotherapie. Ein Leitfaden für Klinik und Praxis. Stuttgart: Kohlhammer, 1989.
41. Möller HJ, von Zerssen D. Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Berlin, Heidelberg, New York: Springer, 1986.
42. Müller P. Die Patienten und das Ergebnis der Rezidivprophylaxe. In: Müller P (Hrsg.) Zur Rezidivprophylaxe schizophrener Psychosen. Stuttgart: Enke, 1982:15-23.
43. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand Suppl 2000;102:83-6.
44. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:266-9.
45. Rifkin A, Quitkin F, Rabiner CJ, Klein DF. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch Gen Psychiatry 1977;34:43-7.
46. Rosenheck R, Evans D, Herz L, Cramer J, et al. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophr Bull 1999;25:709-19.
47. Rosenheck R, Change S, Choe Y, Cramer J, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000;61: 382-6.
48. Schooler NR, Levine J, Severe JB, Brauzer B, et al. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980;37:16-24.
49. Speller JC, Barnes TRE, Curson DA, Pantelis C, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997;171:564-8.
50. Tamminga CA, Thaker GK, Moran M, Kakigi T, et al. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(Suppl B): 102-6.
51. Tran PV, Dellva MA, Tollefson GD, Wentley AL, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505.
52. Volz HP, Kasper S, Möller HJ, Sachs G, et al. Die Rolle der Kognition in der Therapie schizophrener Störungen. Wiesbaden: Deutscher Universitäts-Verlag, 2003.